术前胃镜及活检证实胃窦部腺癌（）课件.ppt

1、Patient T,Female,45 years old 胡某胡某,女，女，45岁岁The gastroscope and biopsy before surgery:gastric sinus adenocarcinoma 术前胃镜及活检证实胃窦部腺癌术前胃镜及活检证实胃窦部腺癌Sep.2004 received radical resection of gastric cancer 2004年年9月接受了胃癌根治术月接受了胃癌根治术Pathological Report:Ulcerative Adenocarcinoma,low differentiation,invades seros

2、a layer,adherence with adjacent pancreas,lymph nodes metastasis 12/16 病理报告：低分化溃疡型腺癌，侵犯浆膜层，与胰腺粘连，病理报告：低分化溃疡型腺癌，侵犯浆膜层，与胰腺粘连，淋巴结转移灶淋巴结转移灶12/16Stage:T4N2M0，G3,Stage IV 分期分期IV期，期，T4N2M0，G3Patient CharacteristicsCompleted chemotherapy regimen(MMC+CF+5-FU)4cycles after surgery 手术后完成手术后完成4个周期个周期(MMC+CF+5-FU

3、)方案的辅助化疗方案的辅助化疗Physical examination at the 6th month after chemotherapy finds the left-supraclavicular lymph nodes(size:2cm).CT Scan:two lymph nodes behind posterior peritoneum involved(size:3cm and 2.5cm)术后术后6个月复诊时体检发现左侧锁骨上淋巴结肿大，个月复诊时体检发现左侧锁骨上淋巴结肿大，2cm。CT扫描发现腹膜后两个肿大淋巴结，扫描发现腹膜后两个肿大淋巴结，3 cm及及2.5cmCA1

4、99：305u/L CEA:126ng/mlPrior TreatmentWhats your Recommend Regimen?Single agent?1、Xeloda 1250mg/m2,twice daily,14days,6 cycles Combination regimens?2、DF(cisplatin+5-FU)3、Xeloda+cisplatin 4、FOLFOX(5-FU/LV+Oxaliplatin)5、Irinotecan-based regimen 6、Taxane-based regimen0%0%10.3%41.4%0%48.3%Actual Treatmen

5、t Patient received Xeloda+cisplatin regimen as first-line chemotherapy Xeloda:1000mg/m2,twice daily,14days cisplatin:75mg/m2,day1 every 3 weeks Patient complained that the adverse reaction of nause and vomiting of cisplatin was too painful for her to go on with more treatment.Only completed 2 cycles

6、.患者由于顺铂所致的恶心呕吐反应过重，只进行了患者由于顺铂所致的恶心呕吐反应过重，只进行了 两个周期的化疗。两个周期的化疗。Physical examination:left-supraclavicular lymph nodes(size:1cm).CT Scan:two lymph nodes behind posterior peritoneum involved shrink obviously,(size:2cm and 1cm)CA199:102u/L CEA:21ng/ml Partial ResponseActual Response1、Maintain Xeloda and

7、cisplatin dosage?因原方案有效维持原方案化疗？因原方案有效维持原方案化疗？2、Reduce cisplatin dosage to 75%and continue?将顺铂剂量减为原剂量的将顺铂剂量减为原剂量的75%后继续治疗？后继续治疗？3、Interrupt？中断治疗中断治疗4、Change drug？更换药物更换药物What to do next?6.3%40.6%0%53.1%Change drug Patient received XELOX Xeloda:1000mg/m2,twice daily,14days Oxaliplatin:130mg/m2,day1 ev

8、ery 3 weeks Completed 4 cyclesActual Treatment The mild symptoms of erythema and swelling on her hands and feet were be observed after 2 cycles of XELOX.She continued the other 2 cycles of XELOX without dosage reducing or treatment delaying.完成完成2周期后患者有轻微的手足部痛性红斑及肿胀。但这周期后患者有轻微的手足部痛性红斑及肿胀。但这并没有促使化疗减量或

9、延期。并没有促使化疗减量或延期。Insensible feeling of hands and feet caused by oxaliplatin also happened.But mild too.奥沙利铂导致的手足麻木感也很轻微。奥沙利铂导致的手足麻木感也很轻微。Adverse Reaction Physical examination:left-supraclavicular lymph nodes(size:0.5cm).CT Scan:two lymph nodes behind posterior peritoneum involved disappeared,(size:0c

10、m and 0cm)CA199:40u/L CEA:11ng/ml Partial ResponseActual ResponseWhat shall you do after 6 cycles?Maintain therapy?1、Xeloda 1000mg/m2,twice daily,14daysContinue with XELOX 2、Xeloda+OxaliplatinChange to other regimen?3、T+F(5-FU/LV+Taxane)4、FOLIRI(5-FU/LV+Irinotecan)5、Radiotherapy?6、Observe?37.5%21.9%

11、3.1%9.4%6.3%21.9%Patient received palliative radiotherapy the left-supraclavicular area:50GY the area of tumor bed:45GY 患者接受了姑息性放疗，左侧锁骨上区域患者接受了姑息性放疗，左侧锁骨上区域50GY，原瘤床部位原瘤床部位45GY Concurrent chemotherapy Xeloda 900mg/m2,twice daily,14days 2 cycles 希罗达同步增敏化疗希罗达同步增敏化疗2周期周期Actual TreatmentClinical Efficacy

12、 Physical examination:left-supraclavicular lymph nodes disappeared.CT Scan:two lymph nodes behind posterior peritoneum involved disappeared CA199:12u/L CEA:6ng/ml Complete Response Last follow up date:Apr.2006What shall you do next?1、Xeloda 1000mg/m2,twice daily,14days2、Xeloda(5FU)+Oxaliplatin3、othe

13、r regimens 4、Observe?24.2%0%0%75.8%Epa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Ozj4ZKvg1WGrc)SDo9%Ozk5#Lwg1WHsd-TDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBm6!Mxi3YJte+UFqb(QBm7$Nyj3YJuf0VGqb(RCn8

14、%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo9%Ozk5#Lwg1WHsd-TDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZNyj3YJuf0VGqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa

15、&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Ozj4ZKvg1WGrc)SDo9%Ozk5#Lwg1WHsd-TDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBm6!Mxi3YJte+UFqb(QBm7$Nyj3YJuf0VGqb(RCn8%Nyj4ZKvg0VGrc)SDn8

16、%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo9%Ozk5#Lwg1WHsd-TDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb(QBm7

17、$Nyj3YJuf0VGqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6

18、!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XIsd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UIte+UFqb*QBm7$Nyj3YJuf0VGqb(RCn8

19、%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6

20、!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XIsd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5

21、#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8$Nyj4ZNyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7

22、$Nyi3YJuf0VFqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XIsd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6

23、!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8$Nyj4ZKvf0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8

24、%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XIsd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6

25、!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8$Nyj4ZKvf0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8%Nyj4ZKvg0VGrc)SDn8

26、%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XIsd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7

27、$Nyi3YJuf0VFqb(RCn8$Nyj4ZKvf0VGrc)SDn8%RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl6#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0VFqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9

28、&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XIsd-TEpa*PAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$QBm7$Nyj3YJuf0VGqb(RCn8%Nyj4ZKvg0VGrc)SDn8%Ozk5#Kvg1WHsd)SDo9&PAk5#Lwh2XHsd-TEpa&PAl6!Mxh2XIte+UEpa*QBm7!Mxi3YJue+UFqb

29、(RBm7$Nyj4YJuf0VGrb(RCn8%Oyj4ZKvg1VGrc)SDo8%Ozk5#Lvg1WHsd-SDo9&PAl5#Lwh2XItd-TEpa*QAl6!Mxi3XIte+UFqa*QBm7$Nxi3YJuf0UFqb(RCn7$Nyj4ZKuf0VGrc)RCn8%Ozk4ZKvg1WHrc)SDo9&Ozk5#Lwh1WHsd-TEo9&PAl6!Lwh2XIte-TEpa*QBl6!Mxi3YIte+UFqb*QBm7$Nyi3YJuf0V*apET-dtIX2hwL#6lAP&9oDT-dsHW1gvL#5kzO%8oDS)crGV1gvKZ4jyO%8nCR(br

30、GV0fuJY4jyN$7mBR(bqFU+euJY3ixM!7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etIY3ixM!6lBQ*apET-etIX2hwL!6lAP&9oET-dsHW1hwL#5kzO&9oDS)crHW1gvKZ4kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-ds

31、HW1gwL#5kzO%9oDS)crGV1gvKZ4jyO%8nCR(brGV0fuJY4jyN$7mBR(bqFU+euJY3ixM!7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET-etIX2hwL!6lAP&9oET-dsHW1hwL#5kzO&9oDS)crHW1gvKZ4kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+et

32、IX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etIY3ixM!6lBQ*apET-etIX2hwL!6lAP&9oET-dsHW1hwL#5kzO&9oDS)crHW1gvKZ4kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)cr

33、GV1gvKZ4jyO%8nCR(brGV0fuJY4jyN$7mBR(bqFU+euJY3ixM!7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET-etIX2hwL!6lAP&9oET-dsHW1hwL#5kzO&9oDS)crHW1gvKZ4kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dt

34、IX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(brGV0fuJY4jyN$7mBR(bqFU+euJY3ixM!7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9oET-dsHW1hwL#5kzO&9oDS)crHW1gvKZ4kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fu

35、JY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mBR(bqFU+euJY3ixM!7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzO&9oDS)crHW1gv

36、KZ4kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM!7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hw

37、M!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)crHW1gvKZ4kzO%8nCR)crGV0fu

38、KZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apEU+etIX2hxM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hw

39、L#5kzP&9oDS)csHW1gvKZ5kzO%8nCR)crGV0fuKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apFU+etIX2ixM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ix

40、M!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCS)crGV0fvKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apFU+etIX2ixM!6lAP*apET-dsIX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jy

41、N%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apFU+etIX2ixM!6lAP&apET-dsHX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hw

42、M!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCS)crGV0fvKZ4jyN$7nCR(bqFU0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apFU+etIX2ixM!6lAP*apET-dsIX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jy

43、N$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCS)crGV0fvKZ4jyN$8nCR(bqFV0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apFU+etIX2ixM!6lAP*apET-dsIX2hwL#5lAP&9oDS-dsHW1gvK#5kz

44、O%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCS)crGV0fvKZ4jyN$8nCR(bqFV0fuJY3iyN$7mBQ*bqFU+etIX3ixM!6lAQ*apBQ*apFU+etIX2ixM!6lAP*apET-dsIX2hwL#5kAP&9oDS)dsHW1gvK#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ix

45、M!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCS)crGV0fvKZ4jyN$8nCR(bqFV0fuJY3ixN$7mBQ*aqFU+etIX3ixM!6lAQ*apET-dtIX2hwL#6lAP&9oDT-dsHW1gwL#5kzO%9oDS)crGW1gvKZ4jzO%8nCR(crGV0fuJZ4jyN$7mCR(bqFU+fuJY3ixM$7mBQ*apFU+etIX2ixM!6lAP*apET-dsIX2hwL#5lAP&9oDS-dsHW1gvL#5kzO%8nDS)crGV0gvKZ4jyN%8nCR(bqGV0fuJY3jyN$7mBQ(bqFU+etJY3ixM!6mBQ*apET+etIX2hwM!6lAP&9pET-dsHW2hwL#5kzP&9oDS)csHW1gvKZ5kzO%8nCS)crGV0fvKZ4jyN$8nCR(bqFV0fuJY